vs
ANI PHARMACEUTICALS INC（ANIP）与Rocket Lab Corp（RKLB）财务数据对比。点击上方公司名可切换其他公司
ANI PHARMACEUTICALS INC的季度营收约是Rocket Lab Corp的1.4倍（$247.1M vs $179.7M），ANI PHARMACEUTICALS INC净利率更高（11.1% vs -29.5%，领先40.6%），Rocket Lab Corp同比增速更快（35.7% vs 29.6%），ANI PHARMACEUTICALS INC自由现金流更多（$29.1M vs $-114.2M），过去两年Rocket Lab Corp的营收复合增速更高（39.2% vs 34.1%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
Rocket Lab是公开上市的航空航天制造商及发射服务提供商，旗下Electron轨道火箭主打小型卫星发射，截至2026年1月已成功完成超75次任务，是全球现役发射次数最多的小型运载火箭。公司还开发了Electron的亚轨道改型HASTE用作高超音速技术测试平台，下一代可复用中型运载火箭Neutron目前也在研发中。
ANIP vs RKLB — 直观对比
营收规模更大
ANIP
是对方的1.4倍
$179.7M
营收增速更快
RKLB
高出6.1%
29.6%
净利率更高
ANIP
高出40.6%
-29.5%
自由现金流更多
ANIP
多$143.3M
$-114.2M
两年增速更快
RKLB
近两年复合增速
34.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $179.7M |
| 净利润 | $27.5M | $-52.9M |
| 毛利率 | — | 38.0% |
| 营业利润率 | 14.1% | -28.4% |
| 净利率 | 11.1% | -29.5% |
| 营收同比 | 29.6% | 35.7% |
| 净利润同比 | 367.5% | -1.1% |
| 每股收益（稀释后） | $1.14 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPRKLB
| Q4 25 | $247.1M | $179.7M | ||
| Q3 25 | $227.8M | $155.1M | ||
| Q2 25 | $211.4M | $144.5M | ||
| Q1 25 | $197.1M | $122.6M | ||
| Q4 24 | $190.6M | $132.4M | ||
| Q3 24 | $148.3M | $104.8M | ||
| Q2 24 | $138.0M | $106.3M | ||
| Q1 24 | $137.4M | $92.8M |
净利润ANIPRKLB
| Q4 25 | $27.5M | $-52.9M | ||
| Q3 25 | $26.6M | $-18.3M | ||
| Q2 25 | $8.5M | $-66.4M | ||
| Q1 25 | $15.7M | $-60.6M | ||
| Q4 24 | $-10.3M | $-52.3M | ||
| Q3 24 | $-24.2M | $-51.9M | ||
| Q2 24 | $-2.3M | $-41.6M | ||
| Q1 24 | $18.2M | $-44.3M |
毛利率ANIPRKLB
| Q4 25 | — | 38.0% | ||
| Q3 25 | — | 37.0% | ||
| Q2 25 | — | 32.1% | ||
| Q1 25 | — | 28.8% | ||
| Q4 24 | — | 27.8% | ||
| Q3 24 | — | 26.7% | ||
| Q2 24 | — | 25.6% | ||
| Q1 24 | — | 26.1% |
营业利润率ANIPRKLB
| Q4 25 | 14.1% | -28.4% | ||
| Q3 25 | 15.9% | -38.0% | ||
| Q2 25 | 6.6% | -41.3% | ||
| Q1 25 | 13.3% | -48.3% | ||
| Q4 24 | -2.3% | -38.9% | ||
| Q3 24 | -13.8% | -49.5% | ||
| Q2 24 | 3.7% | -40.7% | ||
| Q1 24 | 14.8% | -46.4% |
净利率ANIPRKLB
| Q4 25 | 11.1% | -29.5% | ||
| Q3 25 | 11.7% | -11.8% | ||
| Q2 25 | 4.0% | -46.0% | ||
| Q1 25 | 8.0% | -49.5% | ||
| Q4 24 | -5.4% | -39.5% | ||
| Q3 24 | -16.3% | -49.6% | ||
| Q2 24 | -1.7% | -39.2% | ||
| Q1 24 | 13.2% | -47.7% |
每股收益（稀释后）ANIPRKLB
| Q4 25 | $1.14 | $-0.09 | ||
| Q3 25 | $1.13 | $-0.03 | ||
| Q2 25 | $0.36 | $-0.13 | ||
| Q1 25 | $0.69 | $-0.12 | ||
| Q4 24 | $-0.45 | $-0.11 | ||
| Q3 24 | $-1.27 | $-0.10 | ||
| Q2 24 | $-0.14 | $-0.08 | ||
| Q1 24 | $0.82 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $1.0B |
| 总债务越低越好 | — | $152.4M |
| 股东权益账面价值 | $540.7M | $1.7B |
| 总资产 | $1.4B | $2.3B |
| 负债/权益比越低杠杆越低 | — | 0.09× |
8季度趋势，按日历期对齐
现金及短期投资ANIPRKLB
| Q4 25 | $285.6M | $1.0B | ||
| Q3 25 | $262.6M | $976.7M | ||
| Q2 25 | $217.8M | $688.1M | ||
| Q1 25 | $149.8M | $428.4M | ||
| Q4 24 | $144.9M | $419.0M | ||
| Q3 24 | $145.0M | $442.4M | ||
| Q2 24 | $240.1M | $496.8M | ||
| Q1 24 | $228.6M | $492.5M |
总债务ANIPRKLB
| Q4 25 | — | $152.4M | ||
| Q3 25 | — | $347.0M | ||
| Q2 25 | — | $346.5M | ||
| Q1 25 | — | $345.9M | ||
| Q4 24 | — | $345.4M | ||
| Q3 24 | — | $61.2M | ||
| Q2 24 | — | $64.2M | ||
| Q1 24 | — | $66.8M |
股东权益ANIPRKLB
| Q4 25 | $540.7M | $1.7B | ||
| Q3 25 | $505.8M | $1.3B | ||
| Q2 25 | $436.8M | $688.5M | ||
| Q1 25 | $418.6M | $431.3M | ||
| Q4 24 | $403.7M | $382.5M | ||
| Q3 24 | $405.9M | $419.8M | ||
| Q2 24 | $455.8M | $455.2M | ||
| Q1 24 | $452.0M | $478.9M |
总资产ANIPRKLB
| Q4 25 | $1.4B | $2.3B | ||
| Q3 25 | $1.4B | $2.2B | ||
| Q2 25 | $1.3B | $1.6B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.3B | $1.2B | ||
| Q3 24 | $1.3B | $1.2B | ||
| Q2 24 | $920.8M | $1.2B | ||
| Q1 24 | $914.5M | $1.2B |
负债/权益比ANIPRKLB
| Q4 25 | — | 0.09× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.50× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | 0.15× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $-64.5M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $-114.2M |
| 自由现金流率自由现金流/营收 | 11.8% | -63.6% |
| 资本支出强度资本支出/营收 | 0.5% | 27.6% |
| 现金转化率经营现金流/净利润 | 1.10× | — |
| 过去12个月自由现金流最近4个季度 | $171.4M | $-321.8M |
8季度趋势，按日历期对齐
经营现金流ANIPRKLB
| Q4 25 | $30.4M | $-64.5M | ||
| Q3 25 | $44.1M | $-23.5M | ||
| Q2 25 | $75.8M | $-23.2M | ||
| Q1 25 | $35.0M | $-54.2M | ||
| Q4 24 | $15.9M | $-2.4M | ||
| Q3 24 | $12.5M | $-30.9M | ||
| Q2 24 | $17.4M | $-13.0M | ||
| Q1 24 | $18.3M | $-2.6M |
自由现金流ANIPRKLB
| Q4 25 | $29.1M | $-114.2M | ||
| Q3 25 | $38.0M | $-69.4M | ||
| Q2 25 | $71.8M | $-55.3M | ||
| Q1 25 | $32.5M | $-82.9M | ||
| Q4 24 | $13.5M | $-23.9M | ||
| Q3 24 | $7.7M | $-41.9M | ||
| Q2 24 | $13.0M | $-28.3M | ||
| Q1 24 | $13.7M | $-21.8M |
自由现金流率ANIPRKLB
| Q4 25 | 11.8% | -63.6% | ||
| Q3 25 | 16.7% | -44.8% | ||
| Q2 25 | 34.0% | -38.3% | ||
| Q1 25 | 16.5% | -67.6% | ||
| Q4 24 | 7.1% | -18.1% | ||
| Q3 24 | 5.2% | -40.0% | ||
| Q2 24 | 9.4% | -26.7% | ||
| Q1 24 | 10.0% | -23.5% |
资本支出强度ANIPRKLB
| Q4 25 | 0.5% | 27.6% | ||
| Q3 25 | 2.7% | 29.6% | ||
| Q2 25 | 1.9% | 22.2% | ||
| Q1 25 | 1.3% | 23.4% | ||
| Q4 24 | 1.3% | 16.3% | ||
| Q3 24 | 3.2% | 10.5% | ||
| Q2 24 | 3.2% | 14.4% | ||
| Q1 24 | 3.3% | 20.7% |
现金转化率ANIPRKLB
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
RKLB
| Products | $94.0M | 52% |
| Transferred Over Time | $87.3M | 49% |
